Novo Nordisk The stock has lost 50% of its value in the last year due to a combination of factors: In Q1 2025 U.S
Les personnes souffrant de maladies chroniques, de maladies auto-immunes ou suivant des traitements complexes doivent consulter leur mdecin avant toute prise
Most patients notice increased energy within 2-4 weeks
Field of the invention Background Description of the invention Preparation of Factor VIIa Modified or inactivated FVlla (FVllai) may be produced by the following methods: Inactivation of FVlla by various chloromethyl ketones: The following is a list of embodiments further describing the invention : The present invention also relates to the following aspects: Examples Claims (15) A cation exchange chromatography process for purifying a GLP-1 peptide from a mixture comprising said peptide and related or unrelated impurities, comprising the step of:separating said GLP-1 peptide and said related or unrelated impurities of said mixture by elution in a solution consisting essentially of an organic modifier, water, optionally a salt component, and optionally a buffer, with a linear or step gradient or isocratically in salt component and/or with a linear or step pH-gradient or at a constant pH-value, wherein the pH-gradient or pH-value should be in the range where said peptide has a positive local or overall net charge different from the local or overall positive net charge of said related or unrelated impurities so as to remove said related or unrelated impurities, and wherein the ratio of organic modifier to water, on a weight percent basis, is from 1:99 to 99:1, such as 1:99 to 80:20, 20:80 to 80:20, 30:70 to 70:30, 35:50 to 50:35, or 40:50 to 50:40
